

Seto Wk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9578925/publications.pdf>

Version: 2024-02-01

256
papers

9,490
citations

43973

48
h-index

49773

87
g-index

261
all docs

261
docs citations

261
times ranked

8596
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , The, 2011, 12, 568-574.	5.1	541
2	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. <i>Gut and Liver</i> , 2016, 10, 332-9.	1.4	399
3	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 196-206.	3.7	377
4	Chronic hepatitis B virus infection. <i>Lancet</i> , The, 2018, 392, 2313-2324.	6.3	351
5	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 185-195.	3.7	336
6	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	1.8	291
7	Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3736-3743.	0.8	283
8	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-1304.	0.6	230
9	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	6.1	185
10	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2715-2725.	1.3	168
11	Review article: hepatitis B core-related antigen (<sc>HB</sc>crAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 43-54.	1.9	161
12	Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1264-1271.	0.2	145
13	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. <i>Hepatology</i> , 2011, 54, 829-836.	3.6	135
14	Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. <i>Liver International</i> , 2017, 37, 995-1001.	1.9	132
15	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 275-281.	1.8	126
16	Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1004-1010.e1.	2.4	122
17	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1173-1180.	2.8	110
18	Oral Nucleoside/Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B. <i>American Journal of Gastroenterology</i> , 2013, 108, 942-948.	0.2	108

#	ARTICLE	IF	CITATIONS
19	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e125.	1.3	93
20	Modelling NAFLD disease burden in four Asian regionsâ€”2019â€”2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	1.9	92
21	Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. <i>Hepatology</i> , 2017, 66, 1036-1044.	3.6	89
22	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , 2013, 58, 923-931.	3.6	88
23	Association Between Hepatic Steatosis, Measured by Controlled-Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 575-583.e2.	2.4	86
24	Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 97-104.	1.0	84
25	Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2011, 203, 646-654.	1.9	82
26	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2012, 56, 812-819.	3.6	82
27	Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 800-806.	1.8	82
28	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. <i>Hepatology</i> , 2017, 65, 1451-1461.	3.6	81
29	Nonalcoholic fatty liver disease in Asia: emerging perspectives. <i>Journal of Gastroenterology</i> , 2017, 52, 164-174.	2.3	79
30	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-303.	0.6	78
31	Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 428-434.	1.4	77
32	High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e43087.	1.1	71
33	A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2011, 6, e23077.	1.1	69
34	High prevalence of non-alcoholic fatty liver disease in the Chinese â€” results from the Hong Kong liver health census. <i>Liver International</i> , 2015, 35, 542-549.	1.9	67
35	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. <i>Gut</i> , 2010, 59, 1389-1393.	6.1	65
36	A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e32622.	1.1	65

#	ARTICLE	IF	CITATIONS
37	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
38	Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1766-1773.	0.2	62
39	Acute and chronic liver failure in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 662-669.	1.4	62
40	Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. <i>Journal of Viral Hepatitis</i> , 2017, 24, 654-661.	1.0	62
41	Review article: long-term safety of oral antiviral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 730-737.	1.9	60
42	HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2013, 56, 1695-1703.	2.9	58
43	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1028-1034.	1.4	58
44	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. <i>American Journal of Gastroenterology</i> , 2016, 111, 1788-1795.	0.2	58
45	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. <i>Antiviral Research</i> , 2017, 144, 1-7.	1.9	54
46	Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication. <i>Journal of the National Cancer Institute</i> , 2019, 111, 484-489.	3.0	54
47	Correlation of Liver Stiffness and Histological Features in Healthy Persons and in Patients With Occult Hepatitis B, Chronic Active Hepatitis B, or Hepatitis B Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1116-1122.	0.2	52
48	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , 2013, 59, 709-716.	1.8	52
49	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. <i>Oncotarget</i> , 2015, 6, 34941-34952.	0.8	52
50	HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2167-2179.	3.6	50
51	Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. <i>Gut</i> , 2021, 70, 775-783.	6.1	50
52	Prediction of Sustained Response After Nucleo(s)ide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
53	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e116.	1.3	48
54	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B antigen seroclearance. <i>Hepatology</i> , 2018, 68, 462-472.	3.6	48

#	ARTICLE	IF	CITATIONS
55	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3â€­year followâ€­up study. <i>Journal of Viral Hepatitis</i> , 2011, 18, e200-5.	1.0	47
56	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 449-456.	2.4	47
57	Aspirin and Risk of Gastric Cancer After <i>Helicobacter pylori</i> Eradication: A Territory-Wide Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 743-749.	3.0	46
58	Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. <i>The Lancet Global Health</i> , 2022, 10, e278-e287.	2.9	46
59	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, 738-744.	1.0	42
60	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
61	Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese. <i>PLoS ONE</i> , 2013, 8, e66920.	1.1	42
62	Clarithromycinâ€­Amoxicillinâ€­Containing Triple Therapy: A Valid Empirical Firstâ€­Line Treatment for <i>Helicobacter pylori</i> Eradication in Hong Kong?. <i>Helicobacter</i> , 2009, 14, 505-511.	1.6	41
63	Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. <i>Gut</i> , 2019, 68, 1979-1985.	6.1	41
64	New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia. <i>PLoS ONE</i> , 2014, 9, e86449.	1.1	40
65	Fibrosis evolution in chronic hepatitis B e antigenâ€­negative patients across a 10â€­year interval. <i>Journal of Viral Hepatitis</i> , 2019, 26, 818-827.	1.0	40
66	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	6.1	39
67	Diabetes Increases Risk of Gastric Cancer After <i>Helicobacter pylori</i> Eradication: A Territory-Wide Study With Propensity Score Analysis. <i>Diabetes Care</i> , 2019, 42, 1769-1775.	4.3	39
68	Epidemiology and natural history of Wilsonâ€™s disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. <i>World Journal of Gastroenterology</i> , 2017, 23, 7716-7726.	1.4	39
69	Defining Normal Liver Stiffness Range in a Normal Healthy Chinese Population without Liver Disease. <i>PLoS ONE</i> , 2013, 8, e85067.	1.1	38
70	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 7958.	1.6	38
71	Prognostic Value of Hepatorenal Function By Modified Model for Endâ€­stage Liver Disease (MELD) Score in Patients Undergoing Tricuspid Annuloplasty. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	38
72	Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. <i>Hepatology International</i> , 2020, 14, 35-46.	1.9	37

#	ARTICLE	IF	CITATIONS
73	Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". <i>Journal of Hepatology</i> , 2020, 73, 1573-1574.	1.8	37
74	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , 2013, 19, 8887.	1.4	36
75	Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , 2010, 53, 444-448.	1.8	35
76	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , 2013, 7, 98-105.	1.9	34
77	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1153-1159.	1.5	34
78	Statins Were Associated with a Reduced Gastric Cancer Risk in Patients with Eradicated <i>Helicobacter Pylori</i> Infection: A Territory-Wide Propensity Score Matched Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 493-499.	1.1	34
79	New Biomarkers of Chronic Hepatitis B. <i>Gut and Liver</i> , 2019, 13, 589-595.	1.4	34
80	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011, 55, 522-528.	1.8	33
81	Body mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1071-1079.	1.9	33
82	Application of Big Data analysis in gastrointestinal research. <i>World Journal of Gastroenterology</i> , 2019, 25, 2990-3008.	1.4	33
83	Ketamine-Induced Cholangiopathy: A Case Report. <i>American Journal of Gastroenterology</i> , 2011, 106, 1004-1005.	0.2	32
84	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , 2019, 219, 1924-1933.	1.9	32
85	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	1.9	32
86	ACE (Angiotensin-Converting Enzyme) Inhibitors/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk. <i>Hypertension</i> , 2020, 76, 968-975.	1.3	32
87	RNA interference as a novel treatment strategy for chronic hepatitis B infection. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 408-424.	4.5	32
88	Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. <i>Journal of Gastroenterology</i> , 2021, 56, 479-488.	2.3	31
89	Use of Liver Stiffness Measurement for Liver Resection Surgery: Correlation with Indocyanine Green Clearance Testing and Post-Operative Outcome. <i>PLoS ONE</i> , 2013, 8, e72306.	1.1	30
90	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 501-509.	1.9	30

#	ARTICLE	IF	CITATIONS
91	Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 606-614.	4.2	30
92	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. <i>Hepatology International</i> , 2010, 4, 716-722.	1.9	29
93	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy. <i>Journal of Hepatology</i> , 2011, 54, 195-200.	1.8	29
94	Novel developments of hepatitis B: treatment goals, agents and monitoring tools. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 109-120.	1.3	29
95	Rebound of HBV DNA after cessation of nucleos(tide) analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. <i>JHEP Reports</i> , 2020, 2, 100112.	2.6	29
96	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , 2017, 8, 47507-47517.	0.8	29
97	Epidemiology and clinical features of <i>Shewanella</i> infection over an eight-year period. <i>Scandinavian Journal of Infectious Diseases</i> , 2010, 42, 757-762.	1.5	28
98	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , 2016, 51, 487-495.	2.3	28
99	Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00236.	1.3	27
100	Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2089-2097.	4.3	27
101	Interleukin-1 β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. <i>Oncology Letters</i> , 2016, 11, 2919-2924.	0.8	26
102	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e163.	1.3	26
103	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
104	Role of γ 28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 470-477.	1.0	24
105	Epidemiology, characteristics, and survival of post-colonoscopy colorectal cancer in Asia: A population-based study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1545-1553.	1.4	24
106	Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. <i>Hepatology International</i> , 2021, 15, 901-911.	1.9	24
107	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e100.	1.3	23
108	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 320-325.	1.4	23

#	ARTICLE	IF	CITATIONS
109	Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. <i>World Journal of Hepatology</i> , 2015, 7, 825.	0.8	23
110	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 383-392.	1.0	22
111	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1473-1480.	1.0	22
112	Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. <i>Journal of Hepatology</i> , 2018, 69, 121-128.	1.8	21
113	Entecavir treatment in kidney transplant recipients infected with hepatitis B. <i>Clinical Transplantation</i> , 2014, 28, 1010-1015.	0.8	20
114	Relation of Tricuspid Regurgitation to Liver Stiffness Measured by Transient Elastography in Patients With Left-Sided Cardiac Valve Disease. <i>American Journal of Cardiology</i> , 2016, 117, 640-646.	0.7	20
115	Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1764-1770.	0.2	19
116	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0148493.	1.1	19
117	Prevention and management of hepatitis B virus reactivation in cancer patients. <i>Hepatology International</i> , 2016, 10, 407-414.	1.9	19
118	Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment. <i>Annals of Hematology</i> , 2019, 98, 215-218.	0.8	19
119	Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. <i>Viruses</i> , 2021, 13, 1169.	1.5	19
120	Outcome of Lamivudine-Resistant Chronic Hepatitis B after up to 5 Years of Combination Therapy with Adefovir. <i>Antiviral Therapy</i> , 2012, 17, 1255-1262.	0.6	18
121	New pharmacological approaches to a functional cure of hepatitis B. <i>Clinical Liver Disease</i> , 2016, 8, 83-88.	1.0	18
122	Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 202-206.	0.4	18
123	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. <i>Scientific Reports</i> , 2020, 10, 802.	1.6	18
124	748 OUTCOME OF 4-YEAR TREATMENT OF ENTECAVIR FOR TREATMENT-NAIVE CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2011, 54, S301.	1.8	16
125	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	1.4	16
126	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 397-406.	1.0	16

#	ARTICLE	IF	CITATIONS
127	High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line <i>Helicobacter pylori</i> therapy in southern China: a municipality-wide, multicentre, prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3391-3394.	1.3	16
128	Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 899-908.	1.9	16
129	The Effects of IL-28B and ITPA Polymorphisms on Treatment of Hepatitis C Virus Genotype 6. <i>American Journal of Gastroenterology</i> , 2011, 106, 1007-1008.	0.2	15
130	Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. <i>PLoS ONE</i> , 2014, 9, e99028.	1.1	15
131	Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 88.	2.0	15
132	The use of transient elastography in the management of chronic hepatitis B. <i>Hepatology International</i> , 2011, 5, 868-875.	1.9	14
133	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2017, 52, 1064-1074.	2.3	14
134	Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor- κ B signaling. <i>Journal of Digestive Diseases</i> , 2020, 21, 38-45.	0.7	14
135	Gut microbiome and resistome changes during the first wave of the COVID-19 pandemic in comparison with pre-pandemic travel-related changes. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	14
136	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 1398-1408.	1.4	14
137	Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies. <i>World Journal of Gastroenterology</i> , 2019, 25, 282-286.	1.4	14
138	Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 921-943.	1.9	14
139	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0139478.	1.1	13
140	Chronic liver disease: Global perspectives and future challenges to delivering quality health care. <i>PLoS ONE</i> , 2021, 16, e0243607.	1.1	13
141	Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4715-4726.	1.4	13
142	Mutational analysis for Wilson's disease. <i>Lancet, The</i> , 2009, 374, 662.	6.3	12
143	Profile of pre-S deletions in the natural history of chronic hepatitis B infection. <i>Journal of Medical Virology</i> , 2010, 82, 1843-1849.	2.5	12
144	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years. <i>Hepatology</i> , 2011, 53, 1148-1153.	3.6	12

#	ARTICLE	IF	CITATIONS
145	Application of Coamplification at Lower Denaturation Temperature-PCR Sequencing for Early Detection of Antiviral Drug Resistance Mutations of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3209-3215.	1.8	12
146	Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 789.	1.1	12
147	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , 2019, 13, 148-156.	1.9	12
148	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1817-1823.	1.4	12
149	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. <i>Hepatology International</i> , 2013, 7, 119-126.	1.9	11
150	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 697-707.	1.4	11
151	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. <i>Liver International</i> , 2019, 39, 1217-1225.	1.9	11
152	First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. <i>BMC Gastroenterology</i> , 2021, 21, 123.	0.8	11
153	The effect of intragastric balloon placement on weight loss and type 2 diabetes control. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 162-164.	1.9	10
154	Effect of Hepatitis B Virus Reverse Transcriptase Variations on Entecavir Treatment Response. <i>Journal of Infectious Diseases</i> , 2014, 210, 701-707.	1.9	10
155	Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1638-1645.	1.4	10
156	Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2020, 19, 293-301.	0.4	10
157	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. <i>Liver International</i> , 2016, 36, 642-650.	1.9	9
158	Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 290.e1-290.e3.	2.8	9
159	Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use. <i>Journal of Hepatology</i> , 2018, 68, S87.	1.8	9
160	Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 1513-1524.	0.2	9
161	Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance. <i>PLoS ONE</i> , 2014, 9, e99422.	1.1	9
162	Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 553-564.	4.5	9

#	ARTICLE	IF	CITATIONS
163	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009, 14, 679-685.	0.6	9
164	'Immune tolerance' in HBV infection: danger lurks. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 627-628.	8.2	8
165	Emerging drugs for the treatment of hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 183-193.	1.0	8
166	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 483-491.	1.5	8
167	Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. <i>Hepatology</i> , 2020, 72, 818-828.	3.6	8
168	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1315-1326.	1.1	8
169	Detection of the Hepatitis B Surface Antigen in Patients with Occult Hepatitis B by Use of an Assay with Enhanced Sensitivity. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0220421.	1.8	8
170	Statins associate with lower risk of biliary tract cancers: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2023, 12, 557-568.	1.3	8
171	Stability of hepatitis B surface antigen over time: Implications for studies using stored sera. <i>Journal of Medical Virology</i> , 2011, 83, 1900-1904.	2.5	7
172	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1410-1412.	2.4	7
173	Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2021, 36, 134-145.	1.3	7
174	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7863-7874.	1.4	7
175	Hepatitis B surface antigen levels after hepatitis B antigen seroclearance: a longitudinal follow-up study. <i>Liver International</i> , 2015, 35, 854-859.	1.9	6
176	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. <i>Transplantation</i> , 2017, 101, 2391-2398.	0.5	6
177	Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. <i>Current Hepatology Reports</i> , 2019, 18, 503-511.	0.4	6
178	Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2020, 14, 665-668.	1.4	6
179	Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction. <i>Frontiers in Microbiology</i> , 2022, 13, 813783.	1.5	6
180	Future Prevention and Treatment of Chronic Hepatitis B Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 725-734.	1.1	5

#	ARTICLE	IF	CITATIONS
181	The role of interleukin-27 in predicting spontaneous HBsAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , 2017, 37, 1287-1294.	1.9	5
182	Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: A randomized controlled trial protocol. <i>BMC Public Health</i> , 2020, 20, 1048.	1.2	5
183	Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma. <i>Hepatology International</i> , 2022, 16, 371-380.	1.9	5
184	Hepatitis B virus X protein promotes hepatocarcinogenesis via the activation of HMGA2/STC2 signaling to counteract oxidative stress-induced cell death. <i>Carcinogenesis</i> , 2022, 43, 671-681.	1.3	5
185	Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 127-140.	1.0	5
186	New strategies for the treatment of chronic hepatitis B. <i>Trends in Molecular Medicine</i> , 2022, 28, 742-757.	3.5	5
187	HLA-DP and Î³-interferon receptor gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 533-539.	1.4	4
188	Fatal pancytopenia due to albendazole treatment for strongyloidiasis. <i>IDCases</i> , 2018, 12, 112-116.	0.4	4
189	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 101-106.	1.5	4
190	Long-term data on entecavir treatment for treatment-naïve or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13143.	0.7	4
191	Trends in Liver Transplantation for Chronic Hepatitis B in an Era of Highly Potent Antiviral Therapies. <i>Liver Transplantation</i> , 2021, 27, 134-139.	1.3	4
192	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. <i>PLoS ONE</i> , 2021, 16, e0251552.	1.1	4
193	Phenotypic Changes of PD-1 and GITR in T Cells Are Associated With Hepatitis B Surface Antigen Seroclearance. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e31-e37.	1.1	4
194	Association between antibiotic consumption and colon and rectal cancer development in older individuals: A territory-wide study. <i>Cancer Medicine</i> , 2022, 11, 3863-3872.	1.3	4
195	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013, 7, 327-334.	1.9	3
196	A Territory-Wide Study on the Seroprevalence of Hepatitis B Virus in the General Population after Universal Hepatitis B Immunization ERA in Hong Kong, China. <i>Journal of Hepatology</i> , 2016, 64, S378.	1.8	3
197	Rates of metachronous adenoma after curative resection for left-sided or right-sided colon cancer. <i>Intestinal Research</i> , 2018, 16, 619-627.	1.0	3
198	Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10-year longitudinal study. <i>Journal of Hepatology</i> , 2018, 68, S478.	1.8	3

#	ARTICLE	IF	CITATIONS
199	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019, 220, 940-950.	1.9	3
200	Prognostic value and reversibility of liver stiffness in patients undergoing tricuspid annuloplasty. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 551-559.	0.5	3
201	Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5127-5136.	1.1	3
202	What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China?. <i>Journal of Viral Hepatitis</i> , 2022, 29, 637-645.	1.0	3
203	O009 : A prospective study of hepatitis B reactivation in patients with prior HBV exposure undergoing hematopoietic stem cell transplantation: Reactivation association with graft-versus-host disease. <i>Journal of Hepatology</i> , 2015, 62, S194.	1.8	2
204	Hepatitis B Virus: Asian Perspective. , 2019, , 99-116.		2
205	Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. <i>Hepatology International</i> , 2021, 15, 881-891.	1.9	2
206	Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	2
207	471 HBV DNA Levels Predict Significant Liver Histology for HBeAg-Negative Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2010, 138, S-788.	0.6	1
208	Nucleic Acid Testing for the Detection of HBV DNA. <i>Hepatitis Monthly</i> , 2011, 11, 847-848.	0.1	1
209	772 SERUM HEPATITIS B SURFACE ANTIGEN LEVELS DURING FIVE YEARS ENTECAVIR THERAPY IN ASIAN CHRONIC HEPATITIS B PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S314.	1.8	1
210	773 SERUM HEPATITIS B SURFACE ANTIGEN LEVELS TO GUIDE THE CESSATION OF ENTECAVIR IN HEPATITIS B e ANTIGEN-NEGATIVE CHRONIC HEPATITIS B: AN INTERIM ANALYSIS. <i>Journal of Hepatology</i> , 2013, 58, S315.	1.8	1
211	Reply to Liao et al. <i>Clinical Infectious Diseases</i> , 2013, 57, 622-622.	2.9	1
212	1066 Different Adenoma Recurrence Rates on Surveillance Colonoscopy in Patients With Right- or Left-Sided Colonic Cancer After Curative Colectomy. <i>Gastroenterology</i> , 2016, 150, S210.	0.6	1
213	A territory-wide study on the seroprevalence of hepatitis B and C virus in the general population in Hong Kong, China. <i>Journal of Hepatology</i> , 2017, 66, S682.	1.8	1
214	Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBeAg-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study. <i>Gastroenterology</i> , 2017, 152, S1086.	0.6	1
215	Long-term outcomes and significance of HBeAg Seroclearance in Chronic Hepatitis B: Novel Predictive Scores for HCC and HBsAg seroclearance. <i>Journal of Hepatology</i> , 2018, 68, S486-S487.	1.8	1
216	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3630-3641.	1.1	1

#	ARTICLE	IF	CITATIONS
217	FRI-151-Characterization of regulatory T cells and the role of PD-1 and TNF-alpha in spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e454-e455.	1.8	1
218	Nucleic Acid Testing for the Detection of HBV DNA. <i>Hepatitis Monthly</i> , 2011, 11, 847-848.	0.1	1
219	Response to Liu et al., and Björnsson and Björnsson. <i>American Journal of Gastroenterology</i> , 2021, 116, 1091-1092.	0.2	1
220	The optimal screening strategy for chronic hepatitis B virus infection in China – Authors' reply. <i>The Lancet Global Health</i> , 2022, 10, e793.	2.9	1
221	Enhanced Liver Fibrosis Score Stratifies Hepatocellular Carcinoma Risk in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical Infectious Diseases</i> , 2022, 75, 2257-2259.	2.9	1
222	375 GENERATION OF THE PREDICTION MODELS FOR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B AND EXTERNAL VALIDATION BY INDEPENDENT COHORTS. <i>Journal of Hepatology</i> , 2011, 54, S150-S151.	1.8	0
223	541 SEROLOGIC AND VIROLOGIC KINETICS AFTER STOPPING NUCLEOSIDE ANALOGUE THERAPY IN HEPATITIS B SURFACE ANTIGEN (HBSAG) SEROCLEARANCE. <i>Journal of Hepatology</i> , 2012, 56, S214-S215.	1.8	0
224	779 EFFECTS OF HEPATITIS B VIRUS QUASISPECIES AND REVERSE TRANSCRIPTASE VARIANTS ON TREATMENT RESPONSIVENESS TO ENTECAVIR. <i>Journal of Hepatology</i> , 2013, 58, S317.	1.8	0
225	1335 HIGH PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE CHINESE – RESULTS FROM THE HONG KONG LIVER HEALTH CENSUS. <i>Journal of Hepatology</i> , 2013, 58, S538.	1.8	0
226	P679 LEVEL OF HEPATITIS B SURFACE ANTIGEN AND NOT HBV DNA LEVEL AFTER HBeAg SEROCLEARANCE IS PREDICTIVE OF HBsAg SEROCLEARANCE. <i>Journal of Hepatology</i> , 2014, 60, S295.	1.8	0
227	P175 ASSOCIATION OF METHYLATED HISTONES AND DNA METHYLASES WITH HEPATITIS B VIRUS COVALENTLY CLOSED CIRCULAR DNA AND THEIR ASSOCIATION WITH HEPATITIS B VIRUS REPLICATION. <i>Journal of Hepatology</i> , 2014, 60, S124.	1.8	0
228	P1074 THE EFFECT OF LONG-TERM NUCLEOSIDE/TIDE ANALOGUE TREATMENT ON INTRAHEPATIC HBVDNA AND COVALENTLY CLOSED CIRCULAR DNA IN CHRONIC HEPATITIS B PATIENTS. <i>Journal of Hepatology</i> , 2014, 60, S435.	1.8	0
229	P0333 : An epidemiological association between the trends of nucleoside analogue prescription and liver cancer incidence from 1999 to 2012 in Hong Kong, China. <i>Journal of Hepatology</i> , 2015, 62, S435.	1.8	0
230	P0590 : Modified model for end stage liver disease score accurately predicts death or liver transplantation in acute flares of chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 62, S537.	1.8	0
231	Deep Sequencing Analysis of Hepatitis B Virus Quasispecies Characteristics in the Pre-S Region Prior to Development of Hepatocellular Carcinoma. <i>Journal of Hepatology</i> , 2016, 64, S357.	1.8	0
232	Long-Term Outcome of Hepatitis B E-Antigen Seroclearance in Chronic Hepatitis B – Results from the C.H.E.S.S. Cohort. <i>Journal of Hepatology</i> , 2016, 64, S363.	1.8	0
233	Effect of the Hepatitis B Core Protein C-Terminal Domain Mutations on HBV Transcription. <i>Journal of Hepatology</i> , 2016, 64, S386.	1.8	0
234	Letter: is body mass index really associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 483-483.	1.9	0

#	ARTICLE	IF	CITATIONS
235	A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, e44.	2.4	0
236	Hepatic steatosis via controlled attenuation parameter measurements and diabetes contribute to persistent liver fibrosis in the era of long-term nucleoside analogue therapy for chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S694-S695.	1.8	0
237	No increase in graft fibrosis for hepatitis B surface antigen positive patients after liver transplantation using entecavir monotherapy. <i>Journal of Hepatology</i> , 2017, 66, S184-S185.	1.8	0
238	Identification of hepatitis B X protein regions responsible for the regulation of HBV transcription via histone modification. <i>Journal of Hepatology</i> , 2017, 66, S484.	1.8	0
239	Proteomic profiling of plasma proteins associated with spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S484-S485.	1.8	0
240	Cholangiopathic Patterns Detected by Magnetic Resonance Cholangiography in Recreational Users of Ketamine: A Prospective Study. <i>Gastroenterology</i> , 2017, 152, S499.	0.6	0
241	Magnetic Resonance Enterography Distinguishes Intestinal Tuberculosis from Crohn's Disease in Chinese Patients with Ileocecal Lesions on Colonoscopy. <i>Gastroenterology</i> , 2017, 152, S812-S813.	0.6	0
242	Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study. <i>Gastroenterology</i> , 2017, 152, S1085-S1086.	0.6	0
243	Response to Toyoda et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 970.	0.2	0
244	IDDF2018-ABS-0106â€¦Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
245	Risk Factors for Graft Steatosis after Liver Transplantation using Controlled Attenuation Parameter Measurements. <i>Transplantation</i> , 2018, 102, S863.	0.5	0
246	Association of metabolic adipokines with persistence of fibrosis in chronic hepatitis B during long-term nucleoside analogue therapy. <i>Journal of Hepatology</i> , 2018, 68, S516-S517.	1.8	0
247	Occult hepatitis B infection in hepatocellular carcinoma patients with negative HBsAg. <i>Journal of Hepatology</i> , 2018, 68, S474.	1.8	0
248	Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2018, 68, S496.	1.8	0
249	THU-226-Concomitant diabetes mellitus increases risk of liver fibrosis in treatment-naïve chronic hepatitis B with low viral loads: Results from a matched case-control study. <i>Journal of Hepatology</i> , 2019, 70, e264.	1.8	0
250	THU-236-Integration of HBV DNA near cancer-related genes in HBsAg-negative hepatocellular carcinoma patients. <i>Journal of Hepatology</i> , 2019, 70, e269.	1.8	0
251	FRI-360-The role of Paneth cells in the pathogenesis of non-alcoholic fatty liver disease: A potential gut microbiota-associated mechanism. <i>Journal of Hepatology</i> , 2019, 70, e553.	1.8	0
252	IDDF2019-ABS-0168â€¦Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). , 2019, , .		0

#	ARTICLE	IF	CITATIONS
253	Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1430-1432.	1.9	0
254	Impact of wild-type and carboxyl-terminal truncated hepatitis B virus X on hepatocyte proliferation. <i>World Chinese Journal of Digestology</i> , 2018, 26, 760-768.	0.0	0
255	1509-P: Development of a Noninvasive Fibrosis Score for Chinese Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Diabetes</i> , 2020, 69, .	0.3	0
256	IDDF2020-ABS-0061—Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)., 2020, , .		0